Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Preventing disability in inflammatory bowel disease.

Allen PB, Gower-Rousseau C, Danese S, Peyrin-Biroulet L.

Therap Adv Gastroenterol. 2017 Nov;10(11):865-876. doi: 10.1177/1756283X17732720. Epub 2017 Oct 16. Review.

2.

Functional annotation of structural ncRNAs within enhancer RNAs in the human genome: implications for human disease.

Ren C, Liu F, Ouyang Z, An G, Zhao C, Shuai J, Cai S, Bo X, Shu W.

Sci Rep. 2017 Nov 14;7(1):15518. doi: 10.1038/s41598-017-15822-7.

3.

The future developments in inflammatory bowel disease care.

Irving P.

Frontline Gastroenterol. 2012 Jul;3(Suppl 1):i42-i46. doi: 10.1136/flgastro-2011-100072. Epub 2012 May 31. Review.

4.

Stromal and immune cells in gut fibrosis: the myofibroblast and the scarface.

Valatas V, Filidou E, Drygiannakis I, Kolios G.

Ann Gastroenterol. 2017;30(4):393-404. doi: 10.20524/aog.2017.0146. Epub 2017 Apr 12. Review.

5.

JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.

Danese S, Grisham M, Hodge J, Telliez JB.

Am J Physiol Gastrointest Liver Physiol. 2016 Feb 1;310(3):G155-62. doi: 10.1152/ajpgi.00311.2015. Epub 2015 Nov 25. Review.

6.

IL12p40 regulates functional development of human CD4+ T cells: enlightenment by the elevated expressions of IL12p40 in patients with inflammatory bowel diseases.

Wang X, Wu T, Zhou F, Liu S, Zhou R, Zhu S, Song L, Zhu F, Wang G, Xia B.

Medicine (Baltimore). 2015 Mar;94(10):e613. doi: 10.1097/MD.0000000000000613.

7.

Cytokines and mucosal immunity.

Bamias G, Arseneau KO, Cominelli F.

Curr Opin Gastroenterol. 2014 Nov;30(6):547-52. doi: 10.1097/MOG.0000000000000118. Review.

8.

Inflammatory bowel disease: clinical aspects and treatments.

Fakhoury M, Negrulj R, Mooranian A, Al-Salami H.

J Inflamm Res. 2014 Jun 23;7:113-20. doi: 10.2147/JIR.S65979. eCollection 2014. Review.

9.

Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review.

Bettenworth D, Rieder F.

Fibrogenesis Tissue Repair. 2014 Mar 29;7(1):5. doi: 10.1186/1755-1536-7-5.

10.

Natural history and long-term clinical course of Crohn's disease.

Freeman HJ.

World J Gastroenterol. 2014 Jan 7;20(1):31-6. doi: 10.3748/wjg.v20.i1.31. Review.

11.

Measurement of IL-12 (p40, p35), IL-23p19, and IFN-γ mRNA in duodenal biopsies of cats with inflammatory enteropathy.

Waly NE, Peters IR, Day MJ, Stokes CR, Bailey M, Gruffydd-Jones TJ.

J Vet Intern Med. 2014 Jan-Feb;28(1):42-7. doi: 10.1111/jvim.12221. Epub 2013 Oct 21.

12.

FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents.

Guidi L, Felice C, Procoli A, Bonanno G, Martinelli E, Marzo M, Mocci G, Pugliese D, Andrisani G, Danese S, De Vitis I, Papa A, Armuzzi A, Rutella S.

Biomed Res Int. 2013;2013:286368. doi: 10.1155/2013/286368. Epub 2013 Aug 26.

13.

Unique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's disease.

Breynaert C, Dresselaers T, Perrier C, Arijs I, Cremer J, Van Lommel L, Van Steen K, Ferrante M, Schuit F, Vermeire S, Rutgeerts P, Himmelreich U, Ceuppens JL, Geboes K, Van Assche G.

PLoS One. 2013 Jul 23;8(7):e68876. doi: 10.1371/journal.pone.0068876. Print 2013.

14.

The gut microbiome in intestinal fibrosis: environmental protector or provocateur?

Rieder F.

Sci Transl Med. 2013 Jun 19;5(190):190ps10. doi: 10.1126/scitranslmed.3004731. Review.

15.

Crohn's disease complicated by strictures: a systematic review.

Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ.

Gut. 2013 Jul;62(7):1072-84. doi: 10.1136/gutjnl-2012-304353. Epub 2013 Apr 26. Review.

16.

The microaerophilic microbiota of de-novo paediatric inflammatory bowel disease: the BISCUIT study.

Hansen R, Berry SH, Mukhopadhya I, Thomson JM, Saunders KA, Nicholl CE, Bisset WM, Loganathan S, Mahdi G, Kastner-Cole D, Barclay AR, Bishop J, Flynn DM, McGrogan P, Russell RK, El-Omar EM, Hold GL.

PLoS One. 2013;8(3):e58825. doi: 10.1371/journal.pone.0058825. Epub 2013 Mar 12.

17.

Distinct profiles of effector cytokines mark the different phases of Crohn's disease.

Zorzi F, Monteleone I, Sarra M, Calabrese E, Marafini I, Cretella M, Sedda S, Biancone L, Pallone F, Monteleone G.

PLoS One. 2013;8(1):e54562. doi: 10.1371/journal.pone.0054562. Epub 2013 Jan 17.

18.

Up-regulation and pre-activation of TRAF3 and TRAF5 in inflammatory bowel disease.

Shen J, Qiao YQ, Ran ZH, Wang TR.

Int J Med Sci. 2013;10(2):156-63. doi: 10.7150/ijms.5457. Epub 2013 Jan 3.

19.

Changes of the cytokine profile in inflammatory bowel diseases.

Műzes G, Molnár B, Tulassay Z, Sipos F.

World J Gastroenterol. 2012 Nov 7;18(41):5848-61. doi: 10.3748/wjg.v18.i41.5848. Review.

20.

Crucial steps in the natural history of inflammatory bowel disease.

Latella G, Papi C.

World J Gastroenterol. 2012 Aug 7;18(29):3790-9. doi: 10.3748/wjg.v18.i29.3790. Review.

Supplemental Content

Support Center